Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P81 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy/Immune Checkpoint Inhibitor Single Agent

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P81.01 - Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study.

      00:00 - 00:00  |  Presenter: Yong Qian Shu

      • Abstract

      Loading...

    • +

      P81.02 - Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors

      00:00 - 00:00  |  Presenter: Shikang Zhao

      • Abstract

      Loading...

  • +

    P82 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Radiotherapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P82.01 - Tumor Treating Fields (150 kHz) Concurrent with Immune Check Point Inhibitors for Stage 4 Non-Small Cell Lung Cancer (NSCLC) in Phase 3 LUNAR Study

      00:00 - 00:00  |  Presenter: Ticiana Leal

      • Abstract

      Loading...

    • +

      P82.02 - Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study

      00:00 - 00:00  |  Presenter: Juliana Rodrigues Beal

      • Abstract

      Loading...

    • +

      P82.03 - Immunotherapy in Combination with Hypofractionated Radiotherapy for Lung Cancer: A Real-World Experience

      00:00 - 00:00  |  Presenter: Naveen Mummudi

      • Abstract

      Loading...

    • +

      P82.04 - Adaptive Radiation Therapy with Consolidation Sintilimab in Stage III NSCLC: Challenges in Recruiting Patients for Adjuvant Immunotherapy

      00:00 - 00:00  |  Presenter: Yinnan Meng

      • Abstract

      Loading...

  • +

    P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC

      00:00 - 00:00  |  Presenter: Shengxiang Ren

      • Abstract

      Loading...

    • +

      P83.02 - Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study

      00:00 - 00:00  |  Presenter: Suresh S. Ramalingam

      • Abstract

      Loading...

    • +

      P83.03 - Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation

      00:00 - 00:00  |  Presenter: Guanghui Gao

      • Abstract

      Loading...

    • +

      P83.04 - Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC

      00:00 - 00:00  |  Presenter: Ziyi Xu

      • Abstract

      Loading...

  • +

    P84 - Targeted Therapy - Clinically Focused - ALK

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P84.01 - The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.

      00:00 - 00:00  |  Presenter: Laura Mezquita

      • Abstract

      Loading...

    • +

      P84.02 - A Phase II Trial of Alectinib-Refractory Non-Small-Cell Lung Cancer with EML4-ALK Fusion Genes; Okayama Lung Cancer Study Group 1405

      00:00 - 00:00  |  Presenter: Toshihide Yokoyama

      • Abstract

      Loading...

    • +

      P84.03 - GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

      00:00 - 00:00  |  Presenter: Nir Peled

      • Abstract

      Loading...

    • +

      P84.04 - HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis

      00:00 - 00:00  |  Presenter: Fang Wu

      • Abstract

      Loading...

    • +

      P84.05 - Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

    • +

      P84.06 - Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study

      00:00 - 00:00  |  Presenter: Alexis Cortot

      • Abstract

      Loading...

    • +

      P84.07 - Distribution and Therapeutic Outcomes of Intergenic Sequence-ALK Fusion and Coexisting ALK Fusions in Lung Adenocarcinoma Patients

      00:00 - 00:00  |  Presenter: Meijuan Huang

      • Abstract

      Loading...

    • +

      P84.08 - First-line Brigatinib in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer: A Network Meta-Analysis

      00:00 - 00:00  |  Presenter: Huamao M Lin

      • Abstract

      Loading...

    • +

      P84.09 - Asian Subgroup Analysis of a Phase II Study Evaluating Lorlatinib Efficacy in Previously Treated ALK-Positive Advanced NSCLC

      00:00 - 00:00  |  Presenter: Ross Soo

      • Abstract

      Loading...

    • +

      P84.10 - The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data

      00:00 - 00:00  |  Presenter: Mor Moskovitz

      • Abstract

      Loading...

    • +

      P84.11 - Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States

      00:00 - 00:00  |  Presenter: Huamao M Lin

      • Abstract

      Loading...

    • +

      P84.12 - Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor

      00:00 - 00:00  |  Presenter: Camila Bragança Xavier

      • Abstract

      Loading...

    • +

      P84.13 - Organoid Used as Preclinical Modal in ALK Inhibitor Selection: Report of a Case Harbouring LRRTM4–ALK Fusion

      00:00 - 00:00  |  Presenter: Ziqi Jia

      • Abstract

      Loading...

    • +

      P84.14 - Identification of Mechanisms of Resistance to ALK Inhibitors. Next-Generation Sequencing-Based Liquid Biopsy Profiling.

      00:00 - 00:00  |  Presenter: Atocha Romero

      • Abstract

      Loading...

    • +

      P84.15 - Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China

      00:00 - 00:00  |  Presenter: Xue Yang

      • Abstract

      Loading...

    • +

      P84.16 - Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yago Garitaonaindía

      • Abstract

      Loading...

    • +

      P84.17 - Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC——A Real-World Study in China.

      00:00 - 00:00  |  Presenter: Zihua Zou

      • Abstract

      Loading...

    • +

      P84.18 - Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement

      00:00 - 00:00  |  Presenter: Zhiwei Xiao

      • Abstract

      Loading...

    • +

      P84.19 - A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC

      00:00 - 00:00  |  Presenter: Hazel O'Sullivan

      • Abstract

      Loading...

    • +

      P84.20 - VATS Right Upper Lobectomy for Advanced Non-Small Cell Lung Cancer After ALK-Tyrosine Kinase Inhibitor Administration.

      00:00 - 00:00  |  Presenter: Kozo Yamamoto

      • Abstract

      Loading...

    • +

      P84.21 - Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient

      00:00 - 00:00  |  Presenter: Flavia Amaral Duarte

      • Abstract

      Loading...

    • +

      P84.22 - Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina

      00:00 - 00:00  |  Presenter: Diego Kaen

      • Abstract

      Loading...

    • +

      P84.23 - The Safety and Toxicities of ALK -TKIs in ALK-Positive NSCLC: A Systematic Review and Pool Analysis

      00:00 - 00:00  |  Presenter: Kewei Ma

      • Abstract

      Loading...

  • +

    P85 - Targeted Therapy - Clinically Focused - MET

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P85.01 - Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC

      00:00 - 00:00  |  Presenter: Julien Mazieres

      • Abstract

      Loading...

    • +

      P85.02 - NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker

      00:00 - 00:00  |  Presenter: lunxi Peng

      • Abstract

      Loading...

    • +

      P85.03 - PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation.

      00:00 - 00:00  |  Presenter: Yasuhiro Kato

      • Abstract

      Loading...

    • +

      P85.04 - Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis 

      00:00 - 00:00  |  Presenter: Ji-Youn Han

      • Abstract

      Loading...

    • +

      P85.05 - MET Exon 14 Skipping Mutation Positive Non-Small Cell Lung Cancer: A Population-Based Cohort

      00:00 - 00:00  |  Presenter: Selina K Wong

      • Abstract

      Loading...

    • +

      P85.06 - Clinical and Genomic Features of Middle Intensity cMET Stain of Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Xiaorong Dong

      • Abstract

      Loading...

    • +

      P85.07 - Neutrophils Counts Deregulated by C-met TKIs and the Variation Predicts Treatment Response in NSCLC

      00:00 - 00:00  |  Presenter: Xiao-Rong Yang

      • Abstract

      Loading...

  • +

    P86 - Targeted Therapy - Clinically Focused - New Target

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P86.01 - Phase 1 Study of the AXL Inhibitor DS-1205 in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC

      00:00 - 00:00  |  Presenter: James Chih-Hsin Yang

      • Abstract

      Loading...

    • +

      P86.02 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study

      00:00 - 00:00  |  Presenter: Yan Wang

      • Abstract

      Loading...

    • +

      P86.03 - A Phase 2 Study of Erdafitinib in Patients with Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations

      00:00 - 00:00  |  Presenter: Hussein Sweiti

      • Abstract

      Loading...

    • +

      P86.04 - The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Fen Wang

      • Abstract

      Loading...

    • +

      P86.05 - In Vitro Validation Study for HER2 Mutations Identified in Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

      00:00 - 00:00  |  Presenter: Akira Hamada

      • Abstract

      Loading...

    • +

      P86.06 - A Phase I Study of Anlotinib Combined with Platinum-Pemetrexed in Untreated Non-Squamous Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Meijuan Huang

      • Abstract

      Loading...

    • +

      P86.07 - CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel

      00:00 - 00:00  |  Presenter: Jin Young Hwang

      • Abstract

      Loading...

    • +

      P86.08 - Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors

      00:00 - 00:00  |  Presenter: Alison M Schram

      • Abstract

      Loading...

    • +

      P86.09 - A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Jianping Xiong

      • Abstract

      Loading...

    • +

      P86.10 - Real-World Efficacy and Safety of Anlotinib with and without Immunotherapy in Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Qi Xiong

      • Abstract

      Loading...

    • +

      P86.11 - A Real-World Feasibility Study of Patients with Solid Tumors Harboring NRG1 Gene Fusions: NSCLC Subset Analysis

      00:00 - 00:00  |  Presenter: Ajeet Gajra

      • Abstract

      Loading...

    • +

      P86.12 - Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Nahor Haddish-Berhane

      • Abstract

      Loading...

    • +

      P86.13 - Anlotinib is Active for the Patients Failed from the Prior Bevacizumab Treatment: Anti-Angiogenic Therapy might be Cross-Line Used

      00:00 - 00:00  |  Presenter: Jiang Zhu

      • Abstract

      Loading...

    • +

      P86.14 - Next-Generation Sequencing Guided the Gene Mutations Associated with mTOR-Inhibitors in Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Lin Wu

      • Abstract

      Loading...

    • +

      P86.15 - Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan

      00:00 - 00:00  |  Presenter: Gee-Chen Chang

      • Abstract

      Loading...

    • +

      P86.16 - Rationale of a Phase II Trial of Nivolumab Combined with Anlotinib in Advanced NSCLC Previously Treated with Immunotherapy

      00:00 - 00:00  |  Presenter: Baohui Han

      • Abstract

      Loading...

    • +

      P86.17 - Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases

      00:00 - 00:00  |  Presenter: Yu-ming Jia

      • Abstract

      Loading...

    • +

      P86.18 - Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

      00:00 - 00:00  |  Presenter: Juan Bautista Blaquier

      • Abstract

      Loading...

    • +

      P86.19 - Anlotinib in Advanced Lung Squamous Cell Carcinoma: A Real World Study

      00:00 - 00:00  |  Presenter: shujie Song

      • Abstract

      Loading...

    • +

      P86.20 - The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort

      00:00 - 00:00  |  Presenter: Zhifang Liu

      • Abstract

      Loading...

    • +

      P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC

      00:00 - 00:00  |  Presenter: Shuchen Chen

      • Abstract

      Loading...

    • +

      P86.22 - Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

      00:00 - 00:00  |  Presenter: Yong Fang

      • Abstract

      Loading...

    • +

      P86.23 - Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC

      00:00 - 00:00  |  Presenter: Kewei Ma

      • Abstract

      Loading...

  • +

    P87 - Targeted Therapy - Clinically Focused - RET

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P87.01 - Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)

      00:00 - 00:00  |  Presenter: Nir Peled

      • Abstract

      Loading...

    • +

      P87.02 - AcceleRET Lung: A Phase 3 Study of First-Line Pralsetinib in Patients with RET-Fusion+ Advanced/Metastatic NSCLC

      00:00 - 00:00  |  Presenter: Benjamin Besse

      • Abstract

      Loading...

    • +

      P87.03 - Characteristics and Outcomes of RET-Rearranged Non-Small Cell Lung Cancer from China: A Retrospective Study of Real-World 

      00:00 - 00:00  |  Presenter: mina Zhang

      • Abstract

      Loading...

    • +

      P87.04 - Chemotherapy and Immunotherapy Outcomes of RET-Rearranged Lung Cancers: A Case Series

      00:00 - 00:00  |  Presenter: Estelamari Rodriguez

      • Abstract

      Loading...

    • +

      P87.05 - RET-Rearranged Squamous Cell Carcinoma of the Lung Responding to First-Line Immunotherapy plus Chemotherapy

      00:00 - 00:00  |  Presenter: qing-yun Gao

      • Abstract

      Loading...

  • +

    P88 - Targeted Therapy - Clinically Focused - ROS1

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P88.01 - Comprehensive Profiling of ROS1 Fusions in Chinese Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Hanlin Xu

      • Abstract

      Loading...

    • +

      P88.02 - SDC4-ROS1 Fusion as a Mechanism of Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma

      00:00 - 00:00  |  Presenter: Chun-wei Xu

      • Abstract

      Loading...

    • +

      P88.03 - Asymptomatic COVID-19 in a ROS1 positive Non Small Cell Lung Cancer.

      00:00 - 00:00  |  Presenter: Ananda Datta

      • Abstract

      Loading...

    • +

      P88.04 - Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure.

      00:00 - 00:00  |  Presenter: Takahiko Hashimoto

      • Abstract

      Loading...

    • +

      P88.05 - A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC

      00:00 - 00:00  |  Presenter: Quan Lin

      • Abstract

      Loading...

  • +

    P89 - Targeted Therapy - Clinically Focused - Translational

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P89.01 - Clinical and Genomic Features of EGFR-KDD/EGFR Rearrangements of Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Chengzhi Zhou

      • Abstract

      Loading...

    • +

      P89.02 - The Effect of Racial Diversity on the Landscape of Targetable Genomic Alterations in Patients with Lung Adenocarcinomas

      00:00 - 00:00  |  Presenter: Yanyan Lou

      • Abstract

      Loading...

    • +

      P89.03 - Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System

      00:00 - 00:00  |  Presenter: Desiree Hao

      • Abstract

      Loading...

    • +

      P89.04 - Real-World First Line Targeted Therapy Duration Following ctDNA Testing in Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Chuck H. Hensel

      • Abstract

      Loading...

    • +

      P89.05 - Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis

      00:00 - 00:00  |  Presenter: Kathleen Claire Kerrigan

      • Abstract

      Loading...

    • +

      P89.06 - Prospective Concordance Study of a Multi-Gene PCR Assay and NGS for the Detection of Targetable Gene Alterations in Lung Cancer

      00:00 - 00:00  |  Presenter: Shingo Matsumoto

      • Abstract

      Loading...

    • +

      P89.07 - A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients With NSCLC  

      00:00 - 00:00  |  Presenter: Meizi Jin

      • Abstract

      Loading...

    • +

      P89.08 - Real-World Impact of Plasma Cell-Free DNA Next-Generation Sequencing to Detect Actionable Genomic Alterations in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Beung-Chul Ahn

      • Abstract

      Loading...

    • +

      P89.09 - The Landscape of Kinase Domain Duplication (KDD) in Chinese Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Pingli Wang

      • Abstract

      Loading...

    • +

      P89.10 - Genomic Alteration Features and Targeted Therapy Opportunities of Primary Thoracic Sarcoma Patients

      00:00 - 00:00  |  Presenter: Lixia Ju

      • Abstract

      Loading...

    • +

      P89.11 - Mutational Profile of Multiple Lung Cancers in Xuanwei by Next-Generation Sequencing

      00:00 - 00:00  |  Presenter: Gang Guo

      • Abstract

      Loading...

    • +

      P89.12 - Real World Outcomes in EGFR-Mutant Relapsed and De Novo Stage IV Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Amanda Jane Williams Gibson

      • Abstract

      Loading...

    • +

      P89.13 - Real-World Experience of NGS-Based Molecular Profiling in ‘Triple-Negative’ (EGFR/ALK/ROS1) Advanced NSCLC: Should we keep Testing Smokers?

      00:00 - 00:00  |  Presenter: Francesca Simionato

      • Abstract

      Loading...

    • +

      P89.14 - Preliminary Study on CTCs and CTECs in Non-Small Cell Lung Cancer Received Chemotherapy Combined with Anti-Angiogenic Therapy

      00:00 - 00:00  |  Presenter: LINA Zhang

      • Abstract

      Loading...

    • +

      P89.15 - Multiple Driver Oncogenes from Plasma of NSCLC Patients

      00:00 - 00:00  |  Presenter: Sita Andarini

      • Abstract

      Loading...

    • +

      P89.18 - Comprehensive Molecular Characterization of Chinese Patients with Oesophageal Cancer Related with Age

      00:00 - 00:00  |  Presenter: Lianke Liu

      • Abstract

      Loading...

  • +

    P90 - Targeted Therapy - Clinically Focused - Misc. Topics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P90.01 - Clinical Characteristics and Outcome of Patients with Non-Small Cell Lung Cancer Harboring BRAF Mutations  

      00:00 - 00:00  |  Presenter: mina Zhang

      • Abstract

      Loading...

    • +

      P90.02 - BRAF Mutation And Peridiagnosis Thromboembolic Events In Advanced NSCLC Patients

      00:00 - 00:00  |  Presenter: Inmaculada Aparicio Salcedo

      • Abstract

      Loading...

    • +

      P90.03 - A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

      00:00 - 00:00  |  Presenter: Alex I. Spira

      • Abstract

      Loading...

    • +

      P90.04 - RAS Precision Medicine Trans-Atlantic Partnership: Multi-Centre Pooled Analysis of RAS Pathway Mutations in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Helen Adderley

      • Abstract

      Loading...